Introduction
Angiogenesis is a promising therapeutic target in treatments aimed at inhibiting tumor growth. Since the study published by Folkman in 1971 that demonstrated that tumor growth is angiogenesis-dependent [1] , research has focused on identifying new therapeutic agents that can inhibit angiogenesis. In 2004, bevacizumab was developed as a potent inhibitor of vascular endothelial growth factor (VEGF), and this agent demonstrated modest antitumor activity when combined with chemotherapy. Currently, inhibition of angiogenesis has become a standard treatment option for several tumor types, including colorectal cancer, glioblastoma and ovarian cancer.
Hepatocellular carcinoma (HCC), in which hypervascularization is a major characteristic, has been a candidate for antiangiogenetic therapy. Sorafenib is an anticancer agent that suppresses angiogenesis by inhibiting the activities of RAF kinase and VEGF receptors. Two placebo-controlled, Phase III studies (SHARP and Asia-Pacific) were milestones in the treatment of patients with advanced HCC, revealing that sorafenib caused significant improvements in overall survival [2, 3] . Based on the promising results of these clinical trials, sorafenib has been established as a first-line therapy in patients with advanced HCC. However, the subsequent phase III trial of antiangiogenic agents in HCC has failed to show improved survival compared with the standard treatment. Future research is expected in optimizing the antiangiogenic therapy for HCC to improve survival.
